Program
JL18008
A development code. Also written as “JL18008 20 μg/kg”, “JL18008 40 μg/kg” and “JL18008 70 μg/kg”.
Its studies are mostly in HIV Infections, led by Jecho Biopharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jecho Biopharmaceuticals | 32 open or running | phase 2since Apr 21, 2026 | Jan 29, 2026 | Feb 12, 2027phase 2 · NCT07579741 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2026First study: phase 1 study in HIVFirst studyNCT07443228 · 52 planned
- Apr 21, 2026Phase 2 study in HIV InfectionsPhase 2 reachedNCT07579741 · 30 planned · China
- May 21, 2026Phase 1 study in HIV InfectionsNCT07629310 · 40 enrolled · China
Ahead
- Feb 12, 2027Primary completion: phase 2 study in HIV InfectionsNCT07579741
- Dec 20, 2029Primary completion: phase 1 study in HIVNCT07443228
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07629310HIV Infections · China | 1 | Completed | Aug 5, 2025 | 40 |
| NCT07579741HIV Infections · China | 2 | Recruiting | Feb 12, 2027 | 30 |
| NCT07443228HIV | 1 | Not yet recruiting | Dec 20, 2029 | 52 |
How it is read
Names in the registry
- “JL18008 20 μg/kg”, 2 entries
- “JL18008 40 μg/kg”, 2 entries
- “JL18008 70 μg/kg”, 2 entries
- “JL18008 1 μg/kg”, 1 entry
- “JL18008 5 μg/kg”, 1 entry
Codes read as this program: JL18008.
Conditions, from the studies’ own filings
- HIV Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.